Expert insight 29 May 2017

Life-course vaccination: for today, not tomorrow

Thinking about how to be a healthy older person is like thinking about glaciers crashing into Arctic seas as a result of climate change. Too far away to imagine, and we’ll worry when the effects reach our doorsteps. In reality, the challenge is here today asking all of us, at any age, to look ahead...

Read more
Statement 27 May 2017

WHO WHA 70 agenda item 13.3 Addressing the global shortage of, and access to, medicines and vaccines

Delivered by Laetitia Bigger, Director, Vaccines Policy IFPMA welcomes WHO’s efforts in developing a framework to avert shortages. While supply is one factor, shortages are influenced by a range of issues, such as unpredictable country demand, complex regulatory requirements, and lack of timely communication as referenced in paper A70/20. We call for the timely dialogue...

Read more
Statement 25 May 2017

WHO WHA 70 item 12.5 Review of the Pandemic Influenza Preparedness Framework

Delivered by Paula Barbosa, Manager, Vaccines Policy IFPMA reiterate our support for the aim of the WHO PIP Framework to improve pandemic influenza preparedness and response. We welcome the progress made since the establishment of this Framework and remain committed partners in this initiative. While we continue to support the PIP Framework, we believe there...

Read more
Statement 24 May 2017

WHO WHA 70 Item A70/12 Antimicrobial resistance

Delivered by Nina Grundmann, Manager, Global Health Policy, IFPMA IFPMA commends the World Health Organization on the implementation of its AMR GAP and the 67 Member States which have now completed their national action plans. Our industry is at the forefront of leading action to address AMR and is committed to continuing to engage with...

Read more
Expert insight 24 May 2017

Supply & demand: fighting falsified medicines on two fronts

As falsified medicines are debated this week at the World Health Assembly, IFPMA shares what the biopharmaceutical is doing to combat this risk to individual and public health.    If there’s one place not to take a gamble, it’s on whether or not a medicine is real or falsified. Yet in the last weeks alone...

Read more
Infographic 24 May 2017

IFPMA and IAEA – VUCC Virtual University for Cancer Control

Read more
Statement 23 May 2017

IFPMA Statement on Appointment of Dr Tedros as Director-General of the World Health Organization

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) congratulates Dr Tedros Adhanom Ghebreyesus on his election as Director-General of the World Health Organization. His appointment is a reflection of Dr  Tedros wide-ranging experience in health policy and practice and his qualities of leadership. Thomas Cueni, IFPMA Director General upon the election of Dr Tedros...

Read more
Expert insight 20 May 2017

Medicines are not luxury goods

  I must admit I had been somewhat skeptical about the “WHO Fair Pricing Forum” held last week in Amsterdam. There were multiple reasons for my apprehension. One concern was clearly that the notion of “fair” is pretty much in the eye of the beholder, another was that none of the 300 expected participants had...

Read more
Press release 18 May 2017

New Alliance to Drive and Measure Industry Progress to Curb Antimicrobial Resistance

New Industry Alliance brings together research-based pharmaceutical companies, generics, biotech and diagnostic companies, to drive and measure industry progress to curb antimicrobial resistance. The AMR Industry Alliance will ensure that signatories collectively deliver on the commitments made in the Declaration (January 2016) and the Roadmap (September 2016) and will measure industry’s progress in the fight...

Read more
Video 17 May 2017

IFPMA highlight: From shortages to sustainable supply

Read more
Video 17 May 2017

Geneva Pharma Forum on medicines and vaccines shortages 28 April 2017-edited version

Read more
Video 17 May 2017

Geneva Pharma Forum on medicines and vaccines shortages 28 April 2017-live event

Read more